Posted by Michael Wonder on 21 Aug 2024
PHARMAC proposes to widen access to medicine used in the treatment of heart failure
20 August 2024 - PHARMAC is consulting on plans to widen access to empagliflozin, a medicine used in the treatment of chronic heart failure that would benefit more than 18,000 people in the first year of funding.
If approved, the medicine would be available to people who have chronic heart failure with reduced ejection fraction.
